Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR7 | P34969 | 5/20 | 0.40 |
| ▸ | HTR6 | P50406 | 5/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454477 | 0.88 | SMN1; SMN2 (0.54) | TLR8TLR7PIM1SMN1; SMN2MEN1 | |
| SCHEMBL5032352 | 0.86 | HTR1A (0.50) | TLR8TLR7HTR1ADRD2HTR2A | |
| SCHEMBL30784981 | 0.85 | HTR1A (0.51) | TLR8TLR7HTR1ADRD2HTR2A | |
| SCHEMBL14869530 | 0.77 | CYP1A2 (0.42) | SMN1; SMN2SLC29A1MEN1LMNAKMT2A | |
| SCHEMBL30784994 | 0.75 | HTR1A (0.52) | TLR8TLR7HTR1ADRD2HTR2A | |
| SCHEMBL30785003 | 0.75 | MEN1 (0.52) | SMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL2453958 | 0.75 | PGK1 (0.43) | SMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL14869529 | 0.74 | SMN1; SMN2 (0.47) | TLR8TLR7SMN1; SMN2SLC29A1MEN1 | |
| SCHEMBL2450969 | 0.74 | L3MBTL1 (0.41) | SMN1; SMN2LMNA | |
| SCHEMBL19144867 | 0.74 | CA1 (0.40) | HTR7HTR6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197858-B1 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2014-07-02 | — | — | EP | claimed |
| EP-2197858-B1 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2014-07-02 | — | — | EP | disclosed |
| US-8722674-B2 | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-05-13 | — | — | US | disclosed |
| CN-101796035-B | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same | HANALL PHARMACEUTICAL CO LTD | 2013-12-04 | — | — | CN | disclosed |
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | HANALL PHARMACEUTICAL COMPANY, LTD (KR) | 2011-09-29 | — | — | US | disclosed |
| CN-101796035-A | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same | HANALL PHARMACEUTICAL CO LTD | 2010-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | TP53, TP53BP1, SLC5A1 | TLR8 2210/4885TLR7 1571/4885HTR1A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.